Safety and Tolerability of Combining CGRP Monoclonal Antibodies with Gepants in Patients with Migraine: A Retrospective Study

被引:0
作者
Taoufik Alsaadi
Reem Suliman
Vanessa Santos
Ibrahim Al Qaisi
Princess Carmina
Batool Aldaher
Shadi Haddad
Yazan Bader
机构
[1] American Center for Psychiatry and Neurology,Department of Neurology
来源
Neurology and Therapy | 2024年 / 13卷
关键词
CGRP mAbs; Erenumab; Eptinezumab; Gepants; Migraine; Safety; Tolerability; UAE;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:465 / 473
页数:8
相关论文
共 54 条
[1]  
Goadsby PJ(2002)Migraine—current understanding and treatment N Engl J Med 346 257-270
[2]  
Lipton RB(2022)Migraine: a review on its history, global epidemiology, risk factors, and comorbidities Front Neurol 396 1204-1222
[3]  
Ferrari MD(2020)Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 Lancet 23 34-187
[4]  
Amiri P(2022)The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates J Headache Pain 28 183-32
[5]  
Kazeminasab S(1990)Vasoactive peptide release in the extracerebral circulation of humans during migraine headache Ann Neurol 12 1612-124
[6]  
Nejadghaderi SA(2022)Gepants for acute and preventive migraine treatment: a narrative review Brain Sci 59 20-6
[7]  
Vos T(2019)Targeting CGRP for the prevention of migraine and cluster headache: a narrative review Headache 52 83-2760
[8]  
Lim SS(2013)Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies Clin Pharmacokinet 2 1-1742
[9]  
Abbafati C(2020)Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor Neurol Res Pract 10 2751-67
[10]  
Stovner LJ(2017)Calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab J Pain Res 60 1734-265